PMV Pharmaceuticals director receives 42,000 stock options

PMV Pharmaceuticals director Laurie Stelzer received a grant of stock options to acquire 42,000 shares of common stock.

Rhea-AI Filing Summary

PMV Pharmaceuticals director Laurie Stelzer received a grant of stock options to acquire 42,000 shares of common stock. The options have an exercise price of $1.19 per share and expire on June 4, 2036. All 42,000 options vest on the earlier of June 4, 2027 or the date of the company’s next annual stockholder meeting. Following this award, Stelzer holds 42,000 options directly, reflecting a compensation-related grant rather than any open-market share purchase or sale.

Insider Trade Summary

Grant/Award: 42,000 shares

Grant/Award 1 txn

Insider Stelzer Laurie

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	42,000	$0.00	$0.00

Holdings After Transaction: Stock Option (right to buy) — 42,000 contracts (Direct)

Footnotes (1)

1. F1. Shares subject to the option vest on the earlier of (i) June 4, 2027 or (ii) the date of the Issuer's next annual meeting of stockholders.

Key Figures

Stock options granted: 42,000 options Exercise price: $1.19 per share Options outstanding after grant: 42,000 options +2 more

5 metrics

Stock options granted 42,000 options Grant to director Laurie Stelzer

Exercise price $1.19 per share Stock option strike price

Options outstanding after grant 42,000 options Held directly by Laurie Stelzer

Option expiration date June 4, 2036 End of option term

Latest vesting date June 4, 2027 Vests earlier of this date or next annual meeting

Key Terms

Stock Option (right to buy), vesting, exercise price, expiration date

4 terms

Stock Option (right to buy) financial

"security_title: Stock Option (right to buy)"

vesting financial

"Shares subject to the option vest on the earlier of (i) June 4, 2027"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

exercise price financial

"conversion_or_exercise_price: 1.1900"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

expiration date financial

"expiration_date: 2036-06-04T00:00:00.000Z"

The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did PMV Pharmaceuticals (PMVP) director Laurie Stelzer report on this Form 4?

Laurie Stelzer reported receiving a grant of 42,000 stock options from PMV Pharmaceuticals. These options allow her to buy common shares at $1.19 each as part of equity-based compensation, rather than reflecting an open-market trade or immediate cash transaction.

How many PMV Pharmaceuticals (PMVP) stock options were granted to Laurie Stelzer?

Laurie Stelzer was granted 42,000 stock options linked to PMV Pharmaceuticals common stock. Each option represents the right to buy one share at a fixed $1.19 exercise price, giving her potential future ownership if the options vest and she chooses to exercise.

What is the exercise price of Laurie Stelzer’s PMV Pharmaceuticals (PMVP) options?

The exercise price for Laurie Stelzer’s stock options is $1.19 per share. This means she can buy PMV Pharmaceuticals common stock at $1.19 if she exercises vested options, regardless of the market price at that future time, subject to plan terms.

When do Laurie Stelzer’s PMV Pharmaceuticals (PMVP) stock options vest?

The 42,000 options vest on the earlier of June 4, 2027, or the date of PMV Pharmaceuticals’ next annual stockholder meeting. Vesting means she earns the right to exercise the options, assuming she continues to satisfy applicable service conditions.

When do Laurie Stelzer’s PMV Pharmaceuticals (PMVP) stock options expire?

The options expire on June 4, 2036, if not exercised before that date. After expiration, they can no longer be used to purchase PMV Pharmaceuticals common stock, so their potential value lapses if unexercised by then.

Did Laurie Stelzer buy or sell PMV Pharmaceuticals (PMVP) shares in the market?

This Form 4 reports a grant of stock options, not an open-market trade. The transaction is coded as an acquisition through a grant, meaning it reflects equity compensation rather than Laurie Stelzer buying or selling PMV Pharmaceuticals shares for cash.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/05/2026 - 04:32 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Stelzer Laurie

(Last) (First) (Middle)

C/O PMV PHARMACEUTICALS, INC.

400 ALEXANDER PARK DRIVE, SUITE 301

(Street)

PRINCETON NEW JERSEY 08540

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
PMV Pharmaceuticals, Inc. [ PMVP ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/04/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$1.19	06/04/2026		A		42,000		(1)	06/04/2036	Common Stock	42,000	$0	42,000	D

Explanation of Responses:

1. Shares subject to the option vest on the earlier of (i) June 4, 2027 or (ii) the date of the Issuer's next annual meeting of stockholders.

	/s/ Robert Ticktin, by power of attorney	06/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)